TJXMEDIUM SIGNALFINANCIAL10-K

TJX delivered solid financial growth with double-digit increases across key metrics while expanding its European footprint into Spain.

The consistent growth across revenue, profitability, and cash generation demonstrates TJX's resilient off-price retail model continues to resonate with consumers. The company's strong balance sheet position with increased cash reserves provides flexibility for continued expansion and shareholder returns.

Comparing 2026-03-31 vs 2025-04-02View on EDGAR →
FINANCIAL ANALYSIS

TJX reported broad-based financial strength with net income growing 13% to $5.5B and operating cash flow increasing 12.4% to $6.9B. The balance sheet expanded meaningfully with total assets rising 12.7% to $35.8B, supported by higher inventory levels and cash positions, while stockholders' equity grew 21.4% to $10.2B. The proportional growth in assets, liabilities, and equity suggests disciplined expansion rather than leverage-driven growth.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+21.4%
$8.4B$10.2B

Equity base grew 21.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
+21.4%
$11.0B$13.4B

Current liabilities rose 21.4% — increased short-term obligations, watch current ratio.

Current Assets
Balance Sheet
+17%
$13.0B$15.2B

Current assets grew 17% — improving short-term liquidity or inventory/receivables build.

Cash & Equivalents
Balance Sheet
+16.8%
$5.3B$6.2B

Cash grew 16.8% — improving liquidity position supports investment and shareholder returns.

Inventory
Balance Sheet
+13.6%
$6.4B$7.3B

Inventory built 13.6% — monitor whether demand supports this build or if write-downs may follow.

Net Income
P&L
+13%
$4.9B$5.5B

Net income grew 13% — bottom-line growth signals improving overall business health.

Total Assets
Balance Sheet
+12.7%
$31.7B$35.8B

Asset base grew 12.7% — expansion through organic growth, acquisitions, or capital deployment.

Operating Cash Flow
Cash Flow
+12.4%
$6.1B$6.9B

Operating cash flow grew 12.4% — strong conversion of earnings to cash, healthy business fundamentals.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-04-02
ADDED
There were 1,106,810,654 shares of the registrant s common stock, $1.00 par value, outstanding as of March 20, 2026.
You are encouraged to read our filings with the SEC and any further disclosures we may make in our future reports to the SEC, available at www.sec.gov, on our website, or otherwise, for a discussion of these and other risks and uncertainties.
In this report, fiscal 2026 means the 52-week fiscal year ended January 31, 2026; fiscal 2025 means the 52-week fiscal year ended February 1, 2025 and fiscal 2024 means the 53-week fiscal year ended February 3, 2024.
Fiscal 2027 means the 52-week fiscal year ending January 30, 2027.
Unless otherwise indicated, all store information in this Item 1 is as of January 31, 2026, and references to store square footage are to gross square feet.
+7 more — sign up free →
REMOVED
There were 1,117,100,487 shares of the registrant s common stock, $1.00 par value, outstanding as of March 21, 2025.
You are encouraged to read any further disclosures we may make in our future reports to the SEC, available at www.sec.gov, on our website, or otherwise.
In this report, fiscal 2025 means the 52-week fiscal year ended February 1, 2025; fiscal 2024 means the 53-week fiscal year ended February 3, 2024 and fiscal 2023 means the 52-week fiscal year ended January 28, 2023.
Fiscal 2026 means the 52-week fiscal year ending January 31, 2026.
Unless otherwise indicated, all store information in this Item 1 is as of February 1, 2025, and references to store square footage are to gross square feet.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →